Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415205 | 0.87 | SCN8A (0.43) | CYP2C19KDM4EALDH1A1HSD17B10SCN8A | |
| SCHEMBL345774 | 0.86 | KDM4E (0.58) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL20384958 | 0.86 | KDM4E (0.58) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL16962658 | 0.86 | L3MBTL1 (0.45) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL29617695 | 0.85 | CFTR (0.50) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL4070406 | 0.85 | CFTR (0.62) | KDM4EALDH1A1HPGDCFTRSCN8A | |
| SCHEMBL4638408 | 0.85 | CFTR (0.50) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL10978991 | 0.85 | KDM4E (0.56) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL344681 | 0.85 | MAPT (0.48) | CYP2C19KDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL8260775 | 0.84 | MAPT (0.49) | CYP2C19MAPTPPARAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608217-B2 | Process for producing 4-substituted benzopyran derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-08-19 | — | — | US | claimed |
| US-20030109574-A1 | Process for producing 4-substituted benzopyran derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-06-12 | — | — | US | claimed |
| EP-1298129-A2 | Process for producing 4-sustituted benzopyran derivatives | Central Glass Company, Limited (JP) | 2003-04-02 | — | — | EP | claimed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2385938-B1 | SULFONAMIDE DERIVATIVES | PFIZER LTD (GB) | 2015-03-04 | — | — | EP | disclosed |
| US-8962627-B2 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | PRESTWICK CHEMICAL, INC. (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| EP-2493871-B1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2014-09-03 | — | — | EP | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2264017-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
| WO-2010079443-A1 | SULFONAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| US-6608217-B2 | Process for producing 4-substituted benzopyran derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-08-19 | — | — | US | disclosed |
| US-20030109574-A1 | Process for producing 4-substituted benzopyran derivatives | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1298129-A2 | Process for producing 4-sustituted benzopyran derivatives | Central Glass Company, Limited (JP) | 2003-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | CYP2C19 382/4885KDM4E 4039/4885USP2 2660/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | CYP2C19 382/4885KDM4E 4039/4885USP2 2660/4885 |
| US-20030109574-A1 | Process for producing 4-substituted benzopyran derivatives | ACSL4, HAO2, ACSL6 | CYP2C19 561/4885KDM4E 389/4885USP2 777/4885 |
| US-20110028493-A1 | HETEROCYCLIC DERIVATIVE AND USE THEREOF | PDE3B, PDE5A, PDE2A | CYP2C19 235/4885KDM4E 1877/4885USP2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.